ipamorelin san francisco CJC-1295 & Therapy Ipamorelin (5/10mg) – Nordsci

Medsafe has NOT assessed these products for quality, safety or efficacy

In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding

Contamination with unrelated peptide fragments, incorrect sequence synthesis, and mislabelled concentration are documented concerns across the broader research peptide supply landscape

We also offer flexible payment plans because we get itfirst responders dont all have discretionary income lying around

It is often discussed for recovery, sleep, body composition, and age-related hormone support, but results vary